Azacitidine as maintenance therapy in pediatric de novo acute myeloid leukemia

BackgroundRelapse remains a major challenge in pediatric acute myeloid leukemia (AML), particularly in patients ineligible for hematopoietic stem cell transplantation (HSCT). Hypomethylating agents like azacitidine are hypothesized to target residual disease, but their efficacy and safety as mainten...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chunping Wu, Chunxia Cai, Mei Li, Nainong Li, Yongzhi Zheng, Hao Zheng
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-12-01
Edice:	Frontiers in Immunology
Témata:	pediatric AML azacitidine maintenance measurable residual disease molecular relapse risk stratification
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1696125/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!